Pediatric Praziquantel Consortium

Pediatric Praziquantel Consortium at ASTMH Annual Meeting

03 November 2017

The Pediatric Praziquantel Consortium continues to engage in dialogue with the Neglected Tropical Diseases (NTDs) community and fostering awareness on the Pediatric PZQ formulation program. 

Pediatric Praziquantel Consortium at the World Health Summit

05 October 2017

The Pediatric Praziquantel Consortium will not miss the opportunity to join the World Health Summit (October 15-17, in Berlin), one of the world’s most prominent forums addressing global health issues.

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana. 
Video credit: Shelly Xie



Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more


Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that aims to use small, orally dispersible tablets with an acceptable taste. 

Read more